Disease Landscape and Forecast Insights

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Children with UC have a more-complicated disease course compared with adult patients…

The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…

Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of…

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…

Prostate cancer is the second-most-prevalent cancer in men, significantly impacting male mortality rates. Hormonal therapy is a cornerstone of drug treatment for all stages of prostate cancer…

Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…

Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…

Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla) are modestly effective in reducing cognitive and functional decline, require frequent IV infusions, and carry ARIA-…

Clarivate Epidemiology’s coverage of SCCHN comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of SCCHN for each country, as…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key squamous cell carcinoma of the head and neck patient populations,…

Clarivate Epidemiology’s coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…